
CLAIMS

1. Use of an ATR inhibitor of the formula



822

in the manufacture of a medicament for treating pancreatic cancer in combination with another cancer therapy selected from:

- gemcitabine;
- radiation therapy; and
- both gemcitabine and radiation therapy.

2. The use according to claim 1, comprising sensitising pancreatic cancer cells to the cancer therapy, wherein the cancer therapy is gemcitabine and radiation therapy.

3. The use according to claim 2, wherein the pancreatic cancer cells are hypoxic pancreatic cancer cells.

4. The use according to any one of claims 1-3, wherein the cancer therapy is radiation therapy.

5. The use according to any one of claims 1-3, wherein the cancer therapy is gemcitabine.

6. The use according to claim 1, in combination with both gemcitabine and radiation therapy, comprising sensitizing pancreatic cancer cells to chemoradiation.

7. The use according to claim 1, in combination with radiation therapy, comprising disrupting damage-induced cell cycle checkpoints in pancreatic cancer cells.

8. The use according to claim 1, in combination with radiation therapy, comprising inhibiting repair of DNA damage by homologous recombination in pancreatic cancer cells.